New AstraZeneca Vaccine in Development to Fight South African Variant

Feb.08 — Vaccine developers say they are working on a new shot to combat the South African strain of the coronavirus. Early data suggested AstraZeneca Plc.’s product has limited efficacy against mild diseases caused by the variant. Bloomberg’s Rachel Chang reports on “Bloomberg Daybreak: Middle East.”